SNDX logo

SYNDAX PHARMACEUTICALS INC

SNDXNASDAQ
🏆 #2220 by market capUS Equity
$14.40▲ $0.07 (+0.49%)
Latest quote
🔔
Track SNDX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.5%
7d▲ 6.1%
14d▲ 5.5%
30d▼ 21.0%
ytd▼ 31.5%
1y▲ 9.0%
🏦Market Cap
$1.29B
Small Cap
📈Revenue Growth (YoY)
627.8%
High Growth
📊Gross Margin
97.5%
High
💵FCF Margin
-87.6%
Thin
⚖️P/S Ratio
5.1x
Fair
Otter Score
80
Strong

Trading Snapshot

Day Range
$14.09 – $14.65
52-Week Range
$12.80 – $25.59
Volume (shares)
117,134
Avg Volume (shares)
—
Shares Outstanding
89.3M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$172M
Last Q Revenue
$73M
P/E Ratio
-5.7
P/S Ratio
5.1x
EPS (TTM)
$-2.48
Dividend Yield
0.00%
Dilution (1yr)
+1.0%
SNDX logo

SYNDAX PHARMACEUTICALS INC

SNDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$172M▲ +627.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.0%▼ −0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$273M▼ −19.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$323M▲ +17.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
86.6M▲ +1.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$212M▼ −$20M YoY
StockOtter · stockotter.space

About SYNDAX PHARMACEUTICALS INC

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
80/100
Analyst data unavailable.

Latest News & Updates

News unavailable.